OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches

Figures & data

Table 1 Mechanism of Actions for Available Maintenance Pharmacotherapies for Opioid Addiction

Patients	Treatment	Mechanism of Action	Authors, Year
Opioid addiction	Methadone	µ opioid receptors agonist	Chamorro et al,^Citation13 2012; Kharasch et al,^Citation16 2015; Wang et al,^Citation17 2013
Opioid addiction	Buprenorphine	µ opioid receptors agonist	Berrettini, et al,^Citation15 2017
Opioid addiction	Naltrexone	µ opioid receptors antagonist	Chamorro et al,^Citation13 2012; Berrettini, et al,^Citation15 2017

Chamorro AJ, Marcos M, Mirón-Canelo JA, Pastor I, González-Sarmiento R, Laso FJ. Association of μ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17:505–512. doi:10.1111/j.1369-1600.2012.00442.x22515274

 PubMed Web of Science ®Google Scholar

Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015;123:1142–1153. doi:10.1097/ALN.000000000000086726389554

 PubMed Web of Science ®Google Scholar

Wang SC, Tsou HH, Ho IK, Lin KM, Liu YL. Pharmacogenomics study in a Taiwanese methadone maintenance cohort. J Food Drug Anal. 2013;21:S62–S68. doi:10.1016/j.jfda.2013.09.03625278738

 PubMed Web of Science ®Google Scholar

Berrettini W. A brief review of the genetics and pharmacogenetics of opioid use disorders. Dialogues Clin Neurosci. 2017;19:229.29302220

 PubMed Web of Science ®Google Scholar